Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Dose Finding in Drug Development -

Dose Finding in Drug Development

Naitee Ting (Herausgeber)

Buch | Hardcover
248 Seiten
2006
Springer-Verlag New York Inc.
978-0-387-29074-4 (ISBN)
CHF 249,95 inkl. MwSt
A clinical development program for a new drug can be broadly divided into four phases – namely Phases I, II, III, and IV. Phase I clinical trials are designed to study the clinical pharmacology. Information - tained from these studies will help in designing Phase II studies. If the new drug is approved, then Phase IV studies can be started.
This book emphasizes dose selection issues from a statistical point of view. It presentsstatisticalapplicationsinthedesignandanalysisofdose–responsestudies. The importance of this subject can be found from the International Conference on Harmonization (ICH) E4 Guidance document. Establishing the dose–response relationship is one of the most important act- ities in developing a new drug. A clinical development program for a new drug can be broadly divided into four phases – namely Phases I, II, III, and IV. Phase I clinical trials are designed to study the clinical pharmacology. Information - tained from these studies will help in designing Phase II studies. Dose–response relationshipsareusuallystudiedinPhaseII.PhaseIIIclinicaltrialsarelarge-scale, long-term studies. These studies serve to con?rm ?ndings from Phases I and II. ResultsobtainedfromPhasesI,II,andIIIclinicaltrialswouldthenbedocumented and submitted to regulatory agencies for drug approval. In the United States, - viewers from Food and Drug Administration (FDA) review these documents and make a decision to approve or to reject this New Drug Application (NDA). If the new drug is approved, then Phase IV studies can be started. Phase IV clinical trials are also known as postmarketing studies.

and New Drug Development Process.- Dose Finding Based on Preclinical Studies.- Dose-Finding Studies in Phase I and Estimation of Maximally Tolerated Dose.- Dose-Finding in Oncology—Nonparametric Methods.- Dose Finding in Oncology—Parametric Methods.- Dose Response: Pharmacokinetic–Pharmacodynamic Approach.- General Considerations in Dose–Response Study Designs.- Clinical Trial Simulation—A Case Study Incorporating Efficacy and Tolerability Dose Response.- Analysis of Dose–Response Studies—Emax Model.- Analysis of Dose–Response Studies—Modeling Approaches.- Multiple Comparison Procedures in Dose Response Studies.- Partitioning Tests in Dose–Response Studies with Binary Outcomes.- Analysis of Dose–Response Relationship Based on Categorical Outcomes.- Power and Sample Size for Dose Response Studies.

Reihe/Serie Statistics for Biology and Health
Zusatzinfo XIV, 248 p.
Verlagsort New York, NY
Sprache englisch
Maße 155 x 235 mm
Themenwelt Mathematik / Informatik Mathematik
Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Medizin / Pharmazie Pharmazie
Studium Querschnittsbereiche Epidemiologie / Med. Biometrie
Technik
ISBN-10 0-387-29074-5 / 0387290745
ISBN-13 978-0-387-29074-4 / 9780387290744
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
ein überfälliges Gespräch zu einer Pandemie, die nicht die letzte …

von Christian Drosten; Georg Mascolo

Buch | Hardcover (2024)
Ullstein Buchverlage
CHF 34,95

von Matthias Egger; Oliver Razum; Anita Rieder

Buch | Softcover (2021)
De Gruyter (Verlag)
CHF 67,50